IL1B and chronic kidney disease: A 2017 randomized, double-blind, placebo-controlled trial of more than 10,000 patients with CKD by Ridker et al. showed that the use of a human monoclonal antibody targeting IL-1β was associated with a significant reduction in the recurrence of cardiovascular events in such patients (Kloner, 2020)